Home‐based treatment of cellulitis with twice‐daily cefazolin
- 1 November 1998
- journal article
- clinical trial
- Published by AMPCo in The Medical Journal of Australia
- Vol. 169 (10) , 519-522
- https://doi.org/10.5694/j.1326-5377.1998.tb123398.x
Abstract
Objective To assess the clinical outcome and pharmacokinetics of therapy with cefazolin for patients with cellulitis in a hospital‐in‐the‐home (HIH) program. Design Observational study with outcome data compared with previously published reports of therapy for cellulitis. Setting: A university teaching hospital and HIH unit, July 1996 – December 1997. Participants Patients with cellulitis were eligible for inclusion provided their medical condition was stable, they did not require surgical intervention, and their social circumstances allowed home‐based therapy. Intervention Cefazolin 2g intravenously twice daily, with regular nursing and medical assessment. Main outcome measures Clinical efficacy; peak and trough serum concentrations of cefazolin. Results Fifty‐seven patients (37 were men) with a mean age of 48 years (range, 18–90 years) had 61 episodes of moderate to severe cellulitis (41, lower limb; 17, upper limb; and three, face). They received a median of 11 doses of cefazolin (range, 3–27 doses). Clinical outcomes were: cure in 54, improvement in one, treatment failure in three, and in the remaining three episodes the outcome was indeterminate. Cefazolin concentrations were measured in 27 patients. All peak concentrations were more than 40μg/mL, while trough concentrations were all above the MIC90 of the expected pathogens: median, 3.2μg/mL (range: 0.4–18.5 μg/mL). Cefazolin was well tolerated. Conclusions Twice‐daily cefazolin 2g intravenously is a convenient and effective option for home‐based treatment of patients with cellulitis. Its clinical efficacy is comparable with other treatment regimens.Keywords
This publication has 15 references indexed in Scilit:
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infectionsThe Journal of Emergency Medicine, 1996
- Current and future management of serious skin and skin-structure infectionsThe American Journal of Medicine, 1996
- Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USAEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Cost-effectiveness of outpatient parenteral antibiotics: A review of the literatureThe American Journal of Medicine, 1989
- Savings From Outpatient Antibiotic Therapy for OsteomyelitisJAMA, 1986
- Comparison of Cefonicid and Cefazolin for Treatment of Soft-Tissue InfectionsClinical Infectious Diseases, 1984
- Pharmacokinetic Interpretation of Blood Levels and Urinary Excretion Data for Cefazolin and Cephalothin After Intravenous and Intramuscular Administration in HumansAntimicrobial Agents and Chemotherapy, 1975
- Comparative Serum Levels and Urinary Recovery of Cefazolin, Cephaloridine, and Cephalothin in ManThe Journal of Clinical Pharmacology, 1974
- Pharmacokinetics of Cefazolin Compared with Four Other CephalosporinsThe Journal of Infectious Diseases, 1973